J.P. Morgan Healthcare Conference

AI and machine learning may be the ideal tools to evaluate patient data and predict ideal treatment options.

The CRDMO’s new facility will double chemistry capacity for drug discovery research and scale-up projects.

Dr. Jennifer Levin Carter, founder and CEO of Medzown, discusses what makes precision medicine different from personalized medicine and what how challenges faced in this evolving field can be overcome.

Arthur Tzianabos, CEO, Lifordi Immunotherapeutics, spoke with PharmTech about the company’s immune-directed antibody-drug conjugate (ADC) strategy, the benefits of VISTA-targeted ADCs in drug delivery, and Lifordi’s plans at the JP Morgan Healthcare Conference.

Elisabeth Gardiner, CSO of Tevard Biosciences, discusses how transfer RNA is impacting the development of gene therapies for diseases with unmet needs.

The company’s new AI agent automates labor-intensive processes involved in trial document management.